New drug ARO-HSD tested for fatty liver disease NASH

NCT ID NCT04202354

Completed Disease control Sponsor: Arrowhead Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested an experimental drug called ARO-HSD in 50 healthy volunteers and people with NASH, a serious fatty liver disease. The main goal was to check safety and how the drug moves through the body. It's an early step to see if ARO-HSD might be a future treatment for NASH.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ARO-HSD injection
What this could lead to: If successful, this could point toward a treatment for NASH, a serious liver disease with no approved therapies.
What could go wrong: This is a very early, small study (50 people) focused on safety and dosing, not on curing NASH. Many early-stage drugs fail to show benefit in larger trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-ALCOHOLIC STEATOHEPATITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

metabolic dysfunction-associated steatohepatitis metabolic dysfunction-associated steatotic liver disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-ALCOHOLIC STEATOHEPATITIS

Contacts and locations

Locations

Auckland Clinical Studies

Grafton, Auckland, 1010, New Zealand

More trials for these conditions

Other studies related to the condition(s) this trial covers.